Spondyloarthritis

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

A Mendelian randomization analysis provided new insights into the relationship between inflammatory cytokines and ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.

Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

While Black people are consistently underrepresented, White people are consistently overrepresented in inflammatory arthritis trials for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.

A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.

Patients with psoriatic arthritis and ankylosing spondylitis experienced rapid pain reduction with upadacitinib, regardless of treatment history.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

Promising results were announced by UCB after a Phase 3 study evaluated bimekizumab for non-radiographic axial spondyloarthritis and met all endpoints.

The 2 studies focused on upadacitinib treatment for one group of patients with ankylosing spondylitis and another group of patients with non-radiographic axial spondyloarthritis.

High levels of sedentary activity and low levels of physical activity found in patients with axSpA

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.